Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration
“We have treated mice with a new type of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression”
– Professor Andrew Tobin
An international team of scientists has announced a new advance in the fight against Alzheimer’s disease by identifying a new drug target for not only improving symptoms of brain degeneration – but also to extend the life-span of the terminally ill mice.
The four-year study by Medical Research Council (MRC) scientists based at the MRC Toxicology Unit at the University of Leicester is published in the Journal of Clinical Investigation. The study was led by Professor Andrew Tobin alongside colleagues from pharmaceutical company Eli Lilly and Company and the Monash Institute for Pharmaceutical Sciences in Australia. The project was also partly supported by the Wellcome Trust.
Corresponding author Professor Tobin, who alongside the lead researcher Dr Sophie Bradley has since moved from the University of Leicester to the University of Glasgow, said: “The paper describes drug-like molecules that can restore memory loss and slow progression of prion neurodegenerative disease in a manner that relates to the potential of these drugs in human Alzheimer’s disease.
“We have been using mice whose brain cells are progressively dying, similar to what happens in Alzheimer’s disease. This project focuses on a particular protein in the brain, which is proposed to be involved in Alzheimer’s disease, and as such could be a potential target for new drugs.
“We have treated mice with a new class of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice.”
The researchers state that drugs which activate this protein receptor in the brain have previously been tested in clinical trials for Alzheimer’s disease, and showed positive results with respect to improving cognition, but the patients experienced a large number of adverse side effects. This new class of drug is more selective and does not cause any side-effects when administered to mice in the study.
The study authors believe that this offers hope in the design of new drugs for improving cognition and extending life span.
Professor Tobin said: “This work may provide important information as to whether this protein is a viable drug target in the treatment of diseases associated with the progressive death of brain cells. This is of great importance to society, based on the fact that the treatment options for Alzheimer’s disease are very limited – there are no cures for Alzheimer’s disease and current treatments are focused on relieving some of the symptoms.
“What we have found is a novel class of drugs, called allosteric ligands, that target a protein called the M1 muscarinic receptor, which is present in the brain. Activating this receptor protein can not only improve cognitive function in mice with progressive brain degeneration, but when administered daily, can extend life span.”
The scientists say the work is important because it focuses on identifying a treatment that not only improves symptoms associated with neurodegeneration, like current treatments, but also identifies a new strategy for slowing disease progression and extending life-span.
Professor Tobin said: “Alzheimer’s disease is the most common form of dementia, and it affects an estimated 850,000 people in the UK alone. There are no treatments that can slow or halt the progression of Alzheimer’s, and patients are treated with drugs which temporarily mask the symptoms of the disease. Often these treatments are associated with side-effects which can limit patient compliance.
“I am proud to be involved in a collaboration with researchers across the world to address one of the world’s major healthcare challenges. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression.”
Learn more: Alzheimer’s advance: early stage study in mice show new drugs that restore memory loss and prolong life
[osd_subscribe categories=’alzheimers’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “ALZHEIMERS”‘]
Receive an email update when we add a new ALZHEIMERS article.
The Latest on: Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s
- Alzheimer’s doesn’t cloud Michigan woman’s love for opera singingon April 27, 2024 at 7:00 am
She performed through the 1980s at venues like the Seattle Opera, Carnegie Hall and the Metropolitan Opera House and has a lengthy list of awards and accolades over the years.
- Neuroscientists Warn of 'Cascading' Alzheimer's Risk From These Two Habitson April 27, 2024 at 6:59 am
The habits produce a "synergistic effect" on our risk of developing Alzheimer's Disease and general cognitive decline.
- Challenging Old Theories: Innovative Microscopy Exposes New Alzheimer’s Treatment Pathwayson April 27, 2024 at 3:35 am
Researchers at UC San Diego have utilized advanced imaging techniques to explore the metabolic processes behind Alzheimer's disease, leading to potential new strategies for treatment. Alzheimer's ...
- Commentary: As Alzheimer’s risk grows, caregivers need supporton April 27, 2024 at 2:30 am
According to a new report from the Florida Chapters of the Alzheimer’s Association, an estimated one in eight people are living with Alzheimer’s. More than 840,000 are serving as their unpaid ...
- Alzheimer's All-Star Basketball Classic's founder, Gordon Thomas, inspired by dad's battle with diseaseon April 26, 2024 at 11:50 am
Celeste Taylor, Lester Quinones and Diego Maldonado are just a few of the talented players who have participated in the competitions.
- AI helps researchers uncover gut-brain interactions in Alzheimer'son April 26, 2024 at 10:00 am
AI technology reveals more information about the gut-brain health link in Alzheimer's, suggesting new pathways for research around treatments.
- Sponsored: Take on Alzheimer's campaign aims to make impact with awareness and supporton April 25, 2024 at 5:28 pm
Public Health Physician Lucia Abascal joined host Jessica Wills to share how the Take on Alzheimer's campaign is helping to spread awareness and erase stigmas surrounding the disease. Watch the clips ...
- How TikTok is shaping caregiving narratives for Alzheimer’s, dementiaon April 25, 2024 at 12:00 pm
Thousands of caregivers have built large followings on TikTok, showing how they support family members living with dementia or Alzheimer’s.
- For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Doon April 25, 2024 at 8:00 am
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
via Bing News